Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

(2022) Vicky Makker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma

(2022) Weiran Xu et al.   Frontiers in Oncology

Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

(2021) Xiangyu Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

(2021) Zowi R. Huinen et al.   Nature Reviews Clinical Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression

(2021) Naidong Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake

(2021) Kathy Matuszewska et al.   Cancers

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

(2021) Yudong Su et al.   CLINICAL CANCER RESEARCH

Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study

(2021) Na Zhou et al.   LUNG CANCER

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

(2021) Min Yuan et al.   Frontiers in Oncology

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer

(2020) Mingjie Zhang et al.   Journal for ImmunoTherapy of Cancer

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

(2020) Shaochuan Liu et al.   Cell Death & Disease

Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women

(2020) Yong Won Jin et al.   Cancers

Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer

(2020) Yinli Yang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Basic and Therapeutic Aspects of Angiogenesis Updated

(2020) Guy Eelen et al.   CIRCULATION RESEARCH

Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer

(2019) Sha Zhao et al.   Cancer Immunology Research

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

(2019) Shuang Qin et al.   Journal of Hematology & Oncology

Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade

(2019) Qian Li et al.   CLINICAL CANCER RESEARCH

Redundant angiogenic signaling and tumor drug resistance

(2018) Rajesh N. Gacche et al.   DRUG RESISTANCE UPDATES

Increased vessel perfusion predicts the efficacy of immune checkpoint blockade

(2018) Xichen Zheng et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

(2018) Kaitlin Graham et al.   International Journal of Nanomedicine

Anlotinib for Refractory Advanced Non–Small Cell Lung Cancer in China

(2018) Xin-Zu Chen   JAMA Oncology

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

(2015) Rafael Carretero et al.   NATURE IMMUNOLOGY

In Vivo Imaging of Tumor Physiological, Metabolic, and Redox Changes in Response to the Anti-Angiogenic Agent Sunitinib: Longitudinal Assessment to Identify Transient Vascular Renormalization

(2014) Shingo Matsumoto et al.   ANTIOXIDANTS & REDOX SIGNALING

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Benefits of Vascular Normalization Are Dose and Time Dependent--Letter

(2013) Y. Huang et al.   CANCER RESEARCH

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

(2013) Rakesh K. Jain   JOURNAL OF CLINICAL ONCOLOGY

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-targeted TNF  stabilizes tumor vessels and enhances active immunotherapy

(2012) A. Johansson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

(2011) A. G. Sorensen et al.   CANCER RESEARCH

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH